Hemab Therapeutics (NASDAQ:COAG) Shares Gap Down – Time to Sell?

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG)’s stock price gapped down before the market opened on Wednesday . The stock had previously closed at $31.74, but opened at $29.15. Hemab Therapeutics shares last traded at $28.24, with a volume of 4,535 shares trading hands.

Analysts Set New Price Targets

COAG has been the topic of a number of recent analyst reports. Jefferies Financial Group assumed coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They set a “buy” rating and a $39.00 price target on the stock. The Goldman Sachs Group assumed coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They set a “buy” rating and a $36.00 target price for the company. Evercore began coverage on Hemab Therapeutics in a research note on Tuesday, May 26th. They issued an “outperform” rating and a $50.00 price objective for the company. Zacks Research upgraded shares of Hemab Therapeutics to a “hold” rating in a research report on Wednesday, May 27th. Finally, HC Wainwright started coverage on shares of Hemab Therapeutics in a research note on Wednesday, June 17th. They set a “buy” rating and a $40.00 price objective for the company. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $41.40.

Hemab Therapeutics Stock Down 3.6%

Hemab Therapeutics (NASDAQ:COAG) last announced its quarterly earnings data on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

Insider Activity

In other news, major shareholder Ra Capital Management, L.P. purchased 61,523 shares of the business’s stock in a transaction dated Tuesday, June 16th. The stock was acquired at an average price of $24.98 per share, for a total transaction of $1,536,844.54. Following the acquisition, the insider directly owned 6,444,637 shares of the company’s stock, valued at approximately $160,987,032.26. This represents a 0.96% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last three months, insiders have purchased 2,970,541 shares of company stock worth $55,459,603.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.